U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H15N2O2.Cl
Molecular Weight 182.649
Optical Activity NONE
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARBACHOL

SMILES

[Cl-].C[N+](C)(C)CCOC(N)=O

InChI

InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H

HIDE SMILES / InChI

Molecular Formula C6H15N2O2
Molecular Weight 147.1955
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure.

CNS Activity

Curator's Comment: Carbachol does not pass the blood-brain-barrier (BBB) however it produces cholinergic effects on brain blood vessels from the luminal side, whereas the effects on dural and extracranial vessels are from both the luminal and abluminal side since they are devoid of BBB

Originator

Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550933/

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MIOSTAT

Approved Use

Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.

Launch Date

1972
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Characterisation of acetylcholinesterase release from neuronal cells.
2013-03-25
Antispasmodic effects of eugenol on rat airway smooth muscle.
2011-12
Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs).
2011-09-25
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes.
2011-02-18
Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathways.
2010-12
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010-10
Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase.
2010-09-06
Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae.
2010-08
The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions.
2010-06-15
Structural and functional effects of developmental exposure to ethanol on the zebrafish heart.
2010-06
Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura.
2010-03
Cholinergic responses of ophthalmic arteries in M3 and M5 muscarinic acetylcholine receptor knockout mice.
2009-10
Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells.
2009-08
Muscarinic receptors prevent oxidative stress-mediated apoptosis induced by domoic acid in mouse cerebellar granule cells.
2009-04
The cholinomimetic agent carbachol induces headache in healthy subjects.
2009-02
Enhanced proliferation of SNU-407 human colon cancer cells by muscarinic acetylcholine receptors.
2008-11-30
Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis.
2008-09-25
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells.
2008-07
A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors.
2008-04
Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells.
2007-09
[Effects of carbachol on apoptosis of intestinal epithelial cells after gut ischemia/reperfusion in rat].
2007-08
Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block.
2007-05
Theoretical and experimental investigation of calcium-contraction coupling in airway smooth muscle.
2006
Regeneration of cardiomyocytes from bone marrow: Use of mesenchymal stem cell for cardiovascular tissue engineering.
2003-03
Studies on the development of tolerance and potential spinal neurotoxicity after chronic intrathecal carbachol-antinociception in the rat.
1991-02
Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation.
1990-11-13
Catalepsy induced by carbachol microinjected into the pontine reticular formation of rats.
1990-07-31
Renal function during onset of carbachol-induced hypertension in conscious rats.
1990
Plasma catecholamines and alpha 1-adrenoceptor function in hemodialysis-associated hypotension.
1990
Anatomical analysis of frontal cortex sites at which carbachol induces motor seizures in the rat.
1988-05
The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior.
1988-02-16
Novel 'soft' anticholinergic agents.
1988-02
Cardiovascular effects of cholinergic agents in the ventral-lateral midbrain periaqueductal gray of the rat.
1987-12
Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat.
1987-03
Neuropeptide Y and calcitonin gene-related peptide: effects on glucagon and insulin secretion in the mouse.
1987
Cholinergic induction of seizures in the rat prefrontal cortex.
1986-06-23
Subclassification of muscarinic receptors in the heart, urinary bladder and sympathetic ganglia in the pithed rat. Selectivity of some classical agonists.
1985-12
A crucial epileptogenic site in the deep prepiriform cortex.
1985-10-17
Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens.
1984-10
Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".
1984-09-03
Seizures induced by carbachol, morphine, and leucine-enkephalin: a comparison.
1983-04
Neuropharmacology of the parasitic trematode, Schistosoma mansoni.
1983-01
[Effects of atropine and scopolamine on the aggressive behavior and convulsions induced by carbachol and eserine injected into the cerebral ventricles of the cat].
1980
Evidence that a nigral gabaergic--cholinergic balance controls posture.
1979-01-01
Muscarine- and carbachol-induced aggressions: fear and irritable kinds of aggressions.
1977-12-28
Midbrain interaction with the hypothalamus in expression of aggressive behavior in cats.
1977
Motor disturbances produced by intrastriatal injection of cyclic AMP and cyclic GMP.
1976-11
Spasmolytic constituents of Cedrus deodara (Roxb.) Loud: pharmacological evaluation of himachalol.
1975-02
Sustained atrial fibrillation induced by carbachol, methacholine and bethanechol.
1971-04
Avoidance learning: long-lasting deficits after temporal lobe seizure.
1969-12-12
Patents

Patents

Sample Use Guides

MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01% Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration: Other
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:49:17 GMT 2025
Edited
by admin
on Mon Mar 31 17:49:17 GMT 2025
Record UNII
8Y164V895Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARBASTAT
Preferred Name English
CARBACHOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CARBACHOL [USP-RS]
Common Name English
CARBACHOL [EP MONOGRAPH]
Common Name English
CARBACHOLINE CHLORIDE
Systematic Name English
MIOSTAT
Brand Name English
CARBACHOL [EP IMPURITY]
Common Name English
CARBACHOL [MART.]
Common Name English
NSC-32865
Code English
ETHANAMINIUM, 2-((AMINOCARBONYL)OXY)-N,N,N-TRIMETHYL-, CHLORIDE
Systematic Name English
CARBACHOL [VANDF]
Common Name English
CARBACHOL [HSDB]
Common Name English
Choline chloride, carbamate
Systematic Name English
CARBACHOL CHLORIDE
Common Name English
Carbachol [WHO-DD]
Common Name English
CARBACHOL [JAN]
Common Name English
carbachol [INN]
Common Name English
CARBACHOL [MI]
Common Name English
CARBACHOL [USP MONOGRAPH]
Common Name English
CARBACHOL [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29705
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
WHO-ATC S01EB02
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
WHO-ATC N07AB01
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
NDF-RT N0000175884
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
WHO-VATC QS01EB02
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
WHO-VATC QA03AB92
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
Code System Code Type Description
PUBCHEM
5831
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
NCI_THESAURUS
C47430
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
DRUG BANK
DB00411
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
NSC
32865
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
DAILYMED
8Y164V895Y
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
DRUG CENTRAL
488
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
EVMPD
SUB06087MIG
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
IUPHAR
298
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
MERCK INDEX
m3051
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY Merck Index
MESH
D002217
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL965
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
EPA CompTox
DTXSID9022730
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
CHEBI
3385
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
CAS
51-83-2
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
HSDB
6373
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
RS_ITEM_NUM
1092009
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
RXCUI
1999
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY RxNorm
INN
383
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
FDA UNII
8Y164V895Y
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
LACTMED
Carbachol
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
SMS_ID
100000081628
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-127-3
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
WIKIPEDIA
Carbachol
Created by admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Duration of Action PHARMACOKINETIC INTRAOCULAR ADMINISTRATION
PHARMACOKINETIC